Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. - Wikidata - wikimedia - TriplyDB

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

http://www.wikidata.org/entity/Q38775281

about

Management of intracranial melanomas in the era of precision medicine.Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.Pseudoprogression after glioma therapy: an update.CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report.Mechanisms and Therapy for Cancer Metastasis to the Brain.An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment

P2860

Q44959749-6FF9773D-72E7-42BB-A90C-F9E85079BBF7 Q47825909-04E59866-4E74-4043-91AF-C64A4C8A52BF Q47828100-BFCBD6DC-555F-4ABE-AB13-1B24F639FCFA Q48130815-113F8ACC-1956-457A-BC5E-65D08703D87F Q51746346-74A83A40-F89A-4AF2-9668-ACE0E13E3414 Q54256421-037F6ABB-8409-4BF3-81A6-B80801C8AF93 Q54950354-486C9597-2E94-4D8F-B3DC-AD22961EC766 Q55206910-56CB378B-FEFB-4F70-8E15-FEB99A8FD390 Q55283310-F31002AC-E520-4B2B-ACCC-2D087DCAFB52 Q56889910-DF8C5348-7764-4CA1-B175-FC3EBC4EA9E2 Q58758291-7ABE0175-FC01-49CB-9218-45B9468145ED

P2860

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

http://www.wikidata.org/entity/Q38775281

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

@en

type

label

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

@en

prefLabel

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

@en

P1433

Q38775281-C663CD07-7B54-4740-835A-CD4EE88C7445

P1476

Q38775281-57C48896-BBB3-4904-BF0B-AD958006BC6E

P2093

Q38775281-1EDB26D3-05D9-4420-817B-9A522BDF6D80

Q38775281-20B287B0-C6F3-4B7C-9DD6-6C2F6D2F7A29

Q38775281-4547206A-28C2-4285-9FEC-F0BC85C51258

Q38775281-547C5486-E91A-4493-AA8A-C331A1B0A3AD

Q38775281-5CD4A715-35EF-418F-A3D0-3512AC08A631

Q38775281-5F72FCE8-ABA4-4F49-BF9F-FA3C8C06C6CC

Q38775281-762608C7-249B-42F8-B9E7-0DA3A9D3A341

Q38775281-8381E951-294D-4627-AD3E-D948091E00A5

Q38775281-9DECA0CA-6A12-478D-B803-1908FB6ACA45

Q38775281-E838925D-68D4-482A-8FE7-82F4A38FC16F

P2860

Q38775281-027C729C-0F01-4082-9A7E-C1C4054C8F2A

Q38775281-03CF2B9A-52AD-4FA9-823D-FE58F3A421E9

Q38775281-05C26BD1-0437-4E07-B4AA-097C441C52A2

Q38775281-1030D879-1B4F-4CD0-9A85-09B32A3B1222

Q38775281-199E6351-2582-4831-ACC6-6ADEB6115BF7

Q38775281-1C6EF71B-F747-4ABE-A526-AD4F38DC2DC9

Q38775281-20053686-2256-4AA4-81CF-E3BFADFD400D

Q38775281-314E7F1E-704A-4627-AE2D-547541C26389

Q38775281-36085FBE-2750-423E-B91A-CAFC840C135A

Q38775281-371C62E0-450E-4527-A950-2216EEAC3AB6

P2888

Q38775281-DE92D491-AABB-4E8C-8777-2F9CF062A8E4

P304

Q38775281-3E128B81-505D-4DBA-ADEA-39A6D1EB6DA1

P31

Q38775281-60DA5FE4-C2AD-4991-B799-E27B28EAA179

P356

Q38775281-FAE3F815-4E05-49ED-BCF0-78AA35AADF1C

P407

Q38775281-267BC0E8-858F-4D69-82C3-541C00D86396

P433

Q38775281-98E0B0D1-81CF-48E1-AABF-6A8AB2BE789B

P478

Q38775281-49F03E4E-E817-4556-B7EA-28B4B44BBD7E

P50

Q38775281-1EB41A86-5A1D-4F4A-B53C-E31043841275

Q38775281-5A10BE46-0578-4466-925F-667FB4FE3A5A

Q38775281-5E261354-2DD7-4F4D-ADB8-12FE1B9F6D6E

Q38775281-6502FCB6-D47D-4304-8D45-ACBACE4C0CEB

Q38775281-897AD06E-8BF5-47F8-BFE9-50AA09E18FAB

Q38775281-9AEE1736-5FC4-49F3-8811-B844C8E1F151

Q38775281-B6DBFF53-54D6-44DA-A731-2483644341A7

Q38775281-C8068D5E-376E-4E8E-B996-A43AD063A9AC

P577

Q38775281-CF6498FE-A6C7-4CCA-B3DB-A2495A35CDAD

P6179

Q38775281-6CDBC28A-578A-4A82-B691-6D49859F8396

P698

Q38775281-82B19796-5A7F-4A03-B195-54615AB273B5

P932

Q38775281-5264B71E-226C-4986-8A37-2947F408E495

P356

P1433

British Journal of Cancer

P1476

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

@en

P2093

Alex Guminski

http://www.w3.org/2001/XMLSchema#string

Andrew Haydon

http://www.w3.org/2001/XMLSchema#string

Annie Wong

http://www.w3.org/2001/XMLSchema#string

Catherine Rowe

http://www.w3.org/2001/XMLSchema#string

Martin Drummond

http://www.w3.org/2001/XMLSchema#string

Matteo S Carlino

http://www.w3.org/2001/XMLSchema#string

Oliver Klein

http://www.w3.org/2001/XMLSchema#string

Rajat Rai

http://www.w3.org/2001/XMLSchema#string

Sagun Parakh

http://www.w3.org/2001/XMLSchema#string

Shehara Mendis

http://www.w3.org/2001/XMLSchema#string

P2860

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab in previously untreated melanoma without BRAF mutation

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

P2888

P304

1558-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.142

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Georgina V. Long

Richard F. Kefford

Miles C Andrews

Alexander M Menzies

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085439423

http://www.w3.org/2001/XMLSchema#string

P698

28524161

http://www.w3.org/2001/XMLSchema#string

P932

5518864

http://www.w3.org/2001/XMLSchema#string